Norway Hereditary Angioedema Therapeutics Market Size & Outlook
Norway hereditary angioedema therapeutics market, 2018-2030 (US$M)
Related Markets
Norway hereditary angioedema therapeutics market highlights
- The Norway hereditary angioedema therapeutics market generated a revenue of USD 20.6 million in 2023 and is expected to reach USD 45.3 million by 2030.
- The Norway market is expected to grow at a CAGR of 11.9% from 2024 to 2030.
- In terms of segment, kallikrein inhibitor was the largest revenue generating treatment in 2023.
- Others Treatment is the most lucrative treatment segment registering the fastest growth during the forecast period.
Hereditary angioedema therapeutics market data book summary
| Market revenue in 2023 | USD 20.6 million |
| Market revenue in 2030 | USD 45.3 million |
| Growth rate | 11.9% (CAGR from 2023 to 2030) |
| Largest segment | Kallikrein inhibitor |
| Fastest growing segment | Others Treatment |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others Treatment |
| Key market players worldwide | BioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, CSL Ltd, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Pharming Group, Attune Pharmaceuticals |
Other key industry trends
- In terms of revenue, Norway accounted for 0.7% of the global hereditary angioedema therapeutics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany hereditary angioedema therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 276.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Hereditary Angioedema Therapeutics Market Scope
Hereditary Angioedema Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway hereditary angioedema therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary angioedema therapeutics market will help companies and investors design strategic landscapes.
Kallikrein inhibitor was the largest segment with a revenue share of 45.15% in 2023. Horizon Databook has segmented the Norway hereditary angioedema therapeutics market based on c1-esterase inhibitor, bradykinin b2 receptor antagonist, kallikrein inhibitor, others treatment covering the revenue growth of each sub-segment from 2018 to 2030.
In Norway, the public healthcare system and private health insurance are available. Most of the country's population is covered by the public health insurance system. The quality of insurance service for private versus public is the same.
The healthcare system in Norway follows the principles of free choice of providers and universal access decentralization. It is financed by co-payments, taxation, and income related to employee & employer contributions.
Different terms are used to denote types of prescriptions and how they are reimbursed: Blue prescriptions: Paid by State: The National Insurance Scheme (NIS) covers expenses for medical supplies and medicines prescribed for outpatient use.
Reasons to subscribe to Norway hereditary angioedema therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Norway hereditary angioedema therapeutics market databook
-
Our clientele includes a mix of hereditary angioedema therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway hereditary angioedema therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Norway hereditary angioedema therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Norway hereditary angioedema hae therapeutics market size, by treatment, 2018-2030 (US$M)
Norway Hereditary Angioedema Therapeutics Market Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
